November 01, 2011 09:22 ET

Depression Therapeutics Market to Reach $11 Billion by 2018

ROCKVILLE, MD--(Marketwire - Nov 1, 2011) - has announced the addition of the new report "Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their collection of Pharmaceuticals market reports. For more information, visit

The report is an essential source of information and analysis on the global depression therapeutics market. The report:

  • Identifies the key trends shaping and driving the global depression market
  • Provides insights in to the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
  • Includes valuable insights in to the pipeline products within the global depression market.

According to the publisher of the report, the global depression therapeutics market was valued at $4.6 billion in 2010, and expects it to grow at a compound annual growth rate (CAGR) of 3.2% over the next seven years to reach $10.9 billion by 2018.

The depression therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and AGO178 (in the US), offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact